Supplementary Materials

Supplementary Material for:

mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA-Mutant Breast Cancer

Moshe Elkabets, Sadhna Vora, Dejan Juric, Natasha Morse, Mari Mino-Kenudson, Taru Muranen, Jessica Tao, Ana Bosch Campos, Jordi Rodon, Yasir H. Ibrahim, Violeta Serra, Vanessa Rodrik-Outmezguine, Saswati Hazra, Sharat Singh, Phillip Kim, Cornelia Quadt, Manway Liu, Alan Huang, Neal Rosen, Jeffrey A. Engelman, Maurizio Scaltriti,* José Baselga*

*Corresponding author. E-mail: scaltrim@mskcc.org (M.S.); baselgaj@mskcc.org (J.B.)

Published 31 July 2013, Sci. Transl. Med. 5, 196ra99 (2013)
DOI: 10.1126/scitranslmed.3005747

This PDF file includes:

  • Fig. S1. Cell viability after BYL719 treatment.
  • Fig. S2. Inhibition of pS6(235/6) in sensitive and resistant cells.
  • Fig. S3. Immunostaining of p4EBP1 in JIMT-1 and MCF7 xenografts treated with BYL719.
  • Fig. S4. PI3K/Akt/mTOR pathway inhibition in drug-resistant cells treated with BYL719.
  • Fig. S5. Scheme of the shRNA screen to identify candidate genes for resistance to PI3K inhibition.
  • Fig. S6. Results of the shRNA resensitization screen.
  • Fig. S7. Proliferation of drug-resistant cells treated with BYL719, RAD001, and the combination.
  • Fig. S8. Apoptosis and PI3K/Akt/mTOR pathway inhibition in cells treated with BYL719, RAD001, or the combination.
  • Fig. S9. 3D culture of drug-resistant cells treated with BYL719, RAD001, or the combination.
  • Fig. S10. Biochemical and biological effects of BYL719, RAD001, or the combination on MCF7 parental and drug-resistant cells.
  • Fig. S11. Scheme of the secreted protein screen.
  • Fig. S12. Effects of IGF1 and NRG1 on BYL719-resistant cells.
  • Table S1. List of 132 genes tested in the shRNA screen.
  • Table S2. Antibody information.

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S3. Original data (provided as a separate Excel file).

[Table S3]